AU2002339230A1 - A susceptibility gene for late-onset idiopathic parkinson's disease - Google Patents
A susceptibility gene for late-onset idiopathic parkinson's diseaseInfo
- Publication number
- AU2002339230A1 AU2002339230A1 AU2002339230A AU2002339230A AU2002339230A1 AU 2002339230 A1 AU2002339230 A1 AU 2002339230A1 AU 2002339230 A AU2002339230 A AU 2002339230A AU 2002339230 A AU2002339230 A AU 2002339230A AU 2002339230 A1 AU2002339230 A1 AU 2002339230A1
- Authority
- AU
- Australia
- Prior art keywords
- late
- disease
- susceptibility gene
- idiopathic parkinson
- onset idiopathic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36322002P | 2002-03-08 | 2002-03-08 | |
| US60/363,220 | 2002-03-08 | ||
| PCT/IB2002/004276 WO2003076658A2 (en) | 2002-03-08 | 2002-10-14 | A susceptibility gene for late-onset idiopathic parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002339230A1 true AU2002339230A1 (en) | 2003-09-22 |
Family
ID=27805269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002339230A Abandoned AU2002339230A1 (en) | 2002-03-08 | 2002-10-14 | A susceptibility gene for late-onset idiopathic parkinson's disease |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002339230A1 (en) |
| WO (1) | WO2003076658A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10361258A1 (en) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease |
| DE102004014841B4 (en) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome |
| JP5282228B2 (en) * | 2005-10-21 | 2013-09-04 | 株式会社ファンケル | Atopic dermatitis marker and its application technology |
| EP3255049A1 (en) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| EP3350178B1 (en) | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
| WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| PE20190395A1 (en) | 2016-06-16 | 2019-03-13 | Denali Therapeutics Inc | PYRIMIDIN-2-ILAMINO-1H-PYRAZOLES AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2402735A1 (en) * | 2000-03-13 | 2001-10-04 | Incyte Genomics, Inc. | Human transcription factors |
| AU2001264950A1 (en) * | 2000-05-26 | 2001-12-11 | Duke University | Methods of screening for parkinson's disease |
-
2002
- 2002-10-14 WO PCT/IB2002/004276 patent/WO2003076658A2/en not_active Ceased
- 2002-10-14 AU AU2002339230A patent/AU2002339230A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003076658A3 (en) | 2003-12-31 |
| WO2003076658A2 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0318428D0 (en) | Gene drivers | |
| AU2003231509A1 (en) | Compound exhibiting pgd 2 receptor antagonism | |
| EP1580270A4 (en) | Gene for increasing crop yield and use thereof | |
| AU2002339230A1 (en) | A susceptibility gene for late-onset idiopathic parkinson's disease | |
| AU2002319717A1 (en) | Mutant nurr1 gene in parkinson's disease | |
| AU2003272608A1 (en) | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease | |
| AU2003254146A1 (en) | Methods for the treatment of parkinson's disease | |
| AU2003285346A1 (en) | Regulatory elements in the 5' region of the vr1 gene | |
| AU2003285069A8 (en) | Type 2 diabetes mellitus genes | |
| AU2003264845A1 (en) | Parkinson's disease susceptibility haplotype as a tool for genetic screening | |
| AU2003257651A1 (en) | 4'-thionucleotide | |
| AU2002341044A1 (en) | Methods for detecting parkinson's disease | |
| AU2003251962A1 (en) | Screening for alzheimer's disease | |
| AU2003224826A1 (en) | Endohedral metallofullerene contrast agents | |
| EP1591531A4 (en) | Process for acyl-transfer enzyme reactions with acyl- coenzyme a | |
| AU2003268519A1 (en) | Type 2 diabetes susceptibility genes | |
| GB0410101D0 (en) | Parkinson's disease | |
| AU2003294705A8 (en) | Ntsm gene | |
| AU2003284640A1 (en) | Type 2 diabetes-associated gene | |
| GB0202087D0 (en) | Non-drain 'T' connector | |
| AUPS037102A0 (en) | A novel gene | |
| AU2002331051A1 (en) | An animal model for parkinson's disease | |
| PL356071A1 (en) | Mutbar 1 gene | |
| EP1514924A4 (en) | Novel acylase gene | |
| AU2003267384A1 (en) | Bhyd gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |